DelMar to Present Poster of Clinical Research with VAL-083 in Patients with Chemo-Resistant Glioblastoma ("GBM") at ASCO Annual Meeting April 27, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals Collaborates with Duke University to Explore VAL-083 as a Front-Line Treatment for Glioblastoma Multiforme April 25, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals Announces Closing Of $9,000,000 Public Offering Of Common Stock And Warrants April 21, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals Announces Pricing Of $9,000,000 Public Offering Of Common Stock And Warrants April 13, 2017 • 8:16 AM EDT
DelMar Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants April 12, 2017 • 4:22 PM EDT
DelMar Pharmaceuticals Provides VAL-083 Updates from the Ongoing American Association for Cancer Research (AACR) Annual Meeting April 5, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals Announces Abstract Presentations for the American Association for Cancer Research (AACR) Annual Meeting in April 2017 March 28, 2017 • 8:30 AM EDT
DelMar Pharmaceuticals to Participate in Key Opinion Leader Luncheon on Glioblastoma Multiforme Featuring Dr. James Perry, MD March 2, 2017 • 8:30 AM EST
DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) February 13, 2017 • 8:40 AM EST
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2017 Financial Results February 13, 2017 • 8:15 AM EST